
	Three Months Ended June 30,				Six Months Ended June 30,
	2026		2025		2026		2025
	(in thousands)
Revenue	$	1,014	$	10,739	$	180,140	$	12,503
Less:
Imdusiran clinical development expense	326		1,618		1,217		3,789
AB-101-001 clinical development expense	183		1,738		709		3,637
Other research and development expense	2,389		2,142		5,092		7,031
General and administrative expense	3,867		3,328		9,756		9,160
Restructuring expense	—		165		—		12,538
Other segment expense (1)	234		267		471		590
Add:
Interest income	842		1,042		1,657		2,239
Segment net income (loss)	$	(5,143)	$	2,523	$	164,552	$	(22,003)
Adjustments and reconciling items	—		—		—		—
Consolidated net income (loss)	$	(5,143)	$	2,523	$	164,552	$	(22,003)

(1) Other segment expense includes the change in the fair value of contingent consideration, non-cash interest expenses and foreign currency exchange gains and losses.